The stock of the French pharmaceutical company shows an increase of 3.02% to 27.98 euros mid-session, extending a remarkable upward momentum that has seen it gain 17.76% over the past week.
This daily increase is part of an exceptional medium-term trajectory, with a performance of 72.72% over three months and 82.16% over a year, starkly contrasting with the 5.87% increase of the CAC 40 over the same annual period. Trading volumes remain moderate with only 0.24% of the capital traded, suggesting a rise driven by a limited number of participants. This recent performance resonates with several favorable announcements at the end of September, including the approval in Canada of the LONGAVO treatment developed with partner Teva, as well as the increase by Oddo BHF of its price target from 19 to 27 euros.
Technical Breakthrough
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
Almost there! Check your inbox.
A confirmation email has been sent. Click the link to confirm your subscription.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
From a technical standpoint, breaking through the resistance level at 27.16 euros is a significant signal, with the price now moving in uncharted territory for several months. The Relative Strength Index (RSI) reaches 96, an extreme level that indicates a pronounced overbought condition and suggests a possible short-term technical pause. The stock remains well above its reference moving averages, with a 46% gap compared to the 50-day moving average at 19.15 euros and 71% above the 200-day moving average at 16.36 euros.
Momentum Indicators Confirm Positive Dynamics
Momentum indicators confirm the positive dynamics with a MACD at 2.11, well above its signal line at 1.63, and a positive histogram at 0.47. The Chaikin Money Flow of 0.16 indicates dominant buying flows, while the beta coefficient of 0.02 reveals an almost independence of the stock from the movements of the CAC 40. This low correlation with the general market partly explains MedinCell's ability to maintain its upward trajectory even in a more contrasting market context.
We are pleased with the company’s growth and momentum.
Total income €14,1 million; Revenues €11,6 million (+35 %); UZEDY® royalties €4,2 million; Operating result €(6,6) million (improved 13 % year-over-year); Net result €(16 078) thousand; Cash and low-risk financial investments €53,5 million (incl. €49,8 million cash and €3,7 million low-risk investments); Net financial debt €17 629 thousand; NDA for Olanzapine LAI submitted to FDA on December 9, 2025; AbbVie partnership advancing with regulatory package expected in 2026.
Risks mentioned
Foreign exchange risk: weakness of USD vs EUR impacted revenues and generated ~€1 million FX losses
Dependency on partner commercialization (Teva) for UZEDY® royalties and sales forecasts
Regulatory risk: approvals (e.g., Olanzapine LAI) and acceptance for review uncertain
Financial volatility linked to fair value revaluation of EIB BSA warrants (non-cash €6,8 million impact)
Opportunities identified
Olanzapine LAI: NDA submitted and potential launch could be a major growth catalyst
UZEDY®: upward revision of 2025 net sales forecast by Teva (from $160 million to $190-200 million)
AbbVie partnership: first program advancing toward first-in-human trials (regulatory package expected 2026)
Gates Foundation financing: new $3 million envelope to advance mdc-STM malaria program
Expanded geographic approvals (Canada, South Korea) supporting broader commercialization
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
